ARTICLE SUMMARY:
One of the few positive lessons and resulting benefits from the post-2008 shakeout that saw many venture capitalists exit medtech was a supposed shift away from the “bandwagon” approach that saw too many companies chasing too few dollars. But has the medtech industry learned? Not if you look at what’s happening in mitral valves.
One of the few positive lessons and resulting benefits from the post-2008 shakeout that saw many venture capitalists exit medtech was a supposed change in the approach to medical device investing and innovation.
